 |
|
|
| |
Efficacy, Safety and Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Hepatitis C Genotype 1 Infected Non-cirrhotic Japanese Patients (Phase 2 Portion in Phase 2/3 Combined Study)
|
| |
| |
Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco
Norifumi Kawada1; Fumitaka Suzuki2; Yoshiyasu Karino3; Kazuaki Chayama4; Yoshito Itoh5; Takeshi Okanoue6; Makoto Nakamuta7; Naoyoshi Yatsuzuka8; Go Fujimoto8; Lisa Chiacchierini Lupinacci9; Michael N. Robertson9; Luzelena Caro9; Daniel Tatosian9; Anita Y.M. Howe9; Hiromitsu Kumada2
1Department of Hepatology, Osaka City University Medical School, Osaka, Japan; 2Department of Hepatology, Toranomon Hospital, Tokyo, Japan; 3 Department of Gastroenterology, Sapporo Kosei General Hospital, Hokkaido, Japan; 4Department of Gastroenterology and Metabolism, Hiroshima University, Hiroshima, Japan; 5Department of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Japan;
6 Department of Gastroenterology and Hepatology, Saiseikai Suita Hospital, Osaka, Japan; 7Department of Gastroenterology, Kyushu Medical Center, National Hospital Organization, Fukuoka, Japan; 8MSD K.K., Tokyo, Japan; 9Merck & Co., Inc., Kenilworth, NJ, USA
|
| |
|
|
|
|
|
